News Category
NanoViricides expects to begin a Phase II clinical trial of its oral antiviral NV-387 for Ebola in the Democratic Republic of Congo, highlighting a po...
GeoVax emphasizes the potential of its MVA-based vaccine candidates and expertise to contribute to the global response against the escalating Bundibug...
NanoViricides has received regulatory approval to begin a Phase II clinical trial of its oral antiviral NV-387 for Ebola in the Democratic Republic of...
NanoViricides is awaiting regulatory approval in the DRC to begin a Phase II trial of its NV-387 Oral Gummies for the Bundibugyo ebolavirus, which cur...
NanoViricides has applied to the Democratic Republic of Congo's regulatory agency to begin a Phase II clinical trial of its oral antiviral NV-387 for ...
NanoViricides has received National Ethics Committee approval in the DRC for a Phase II trial of its NV-387 oral gummies to treat Bundibugyo ebolaviru...
The Democratic Republic of Congo's copper and cobalt production remains unaffected by Middle East supply disruptions, with exports increasing, offerin...
NanoViricides progresses its oral gummies formulation of NV-387 toward a Phase II clinical trial for the Bundibugyo ebolavirus outbreak in the DRC, of...
NanoViricides has shipped its broad-spectrum antiviral drug NV-387 to the Democratic Republic of Congo for a Phase II clinical trial against MPox, wit...
NanoViricides announced approval from the DRC Pillar Committee to conduct a Phase II trial of its oral NV-387 Gummies for Bundibugyo ebolavirus, highl...
Redwood AI Corp. announced a letter of intent to develop a regional pathogen tracking and AI-driven outbreak intelligence initiative across Central an...
Trident Digital Tech Holdings Ltd. announced the launch of TDTHAI, an AI platform for enterprise deployment, workflow automation, and digital transfor...
The CDC extends its travel ban on individuals from Uganda, South Sudan, and DRC to include green card holders, raising concerns among healthcare stake...
NanoViricides highlights its broad-spectrum antiviral candidate NV-387 as a potential treatment for the Bundibugyo Ebola outbreak, citing its unique h...
NanoViricides (NYSE American: NNVC) emphasizes the potential of its oral broad-spectrum antiviral candidate NV-387 in response to the Bundibugyo Ebola...
NanoViricides reported progress on NV-387, its broad-spectrum antiviral candidate, including regulatory approval for Phase II trials in the DRC for MP...
Ongoing conflict in Iran is straining the supply of essential leaching chemicals for cobalt and copper miners in the Democratic Republic of Congo, for...
NanoViricides is set to begin a Phase II trial of NV-387 for MPox in the DRC, targeting Clade I MPox, with site preparation and staff training schedul...
The acquisition of Chemaf by US-based Virtus Minerals underscores the strategic importance of securing critical minerals like lithium and cobalt for t...
Easy Environmental Solutions (EZES) capitalizes on Middle East-driven nitrogen shortages and regulatory pressures, deploying its Terreplenish microbia...
NanoViricides announced completion of NV-387 Oral Gummies manufacturing and its upcoming presentation at NIBA conference, advancing its broad-spectrum...
The Democratic Republic of Congo has lifted its 10-month ban on cobalt exports, underscoring the risks of concentrated supply chains for critical mine...
Micropolis AI Robotics (NYSE: MCRP) has entered a $9.3 million, 18-month development program with AfricAI to design three customized unmanned ground v...
